EMA Authorised: Akantior (Polihexanide) — SIFI SPA

View source ↗

Summary

The European Medicines Agency authorised Akantior (polihexanide) from SIFI SPA for the treatment of Acanthamoeba keratitis. It has orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acanthamoeba Keratitis

Drugs mentioned

• Akantior (polihexanide)

Snippet

Status: Authorised. Therapeutic area: Acanthamoeba Keratitis. MAH: SIFI SPA. Decision date: 22/08/2024. Orphan medicine